Anti-RET/ RET V804L/ CDHF12 monoclonal antibody
Anti-RET/ RET V804L/ CDHF12 antibody for FACS & in-vivo assay
Go to RET V804L/RET products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T17566-Ab-1/ GM-Tg-hg-T17566-Ab-2 | Anti-Human RET V804L/RET monoclonal antibody | Human |
GM-Tg-rg-T17566-Ab-1/ GM-Tg-rg-T17566-Ab-2 | Anti-Rat RET V804L/RET monoclonal antibody | Rat |
GM-Tg-mg-T17566-Ab-1/ GM-Tg-mg-T17566-Ab-2 | Anti-Mouse RET V804L/RET monoclonal antibody | Mouse |
GM-Tg-cynog-T17566-Ab-1/ GM-Tg-cynog-T17566-Ab-2 | Anti-Cynomolgus/ Rhesus macaque RET V804L/RET monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T17566-Ab-1/ GM-Tg-felg-T17566-Ab-2 | Anti-Feline RET V804L/RET monoclonal antibody | Feline |
GM-Tg-cang-T17566-Ab-1/ GM-Tg-cang-T17566-Ab-2 | Anti-Canine RET V804L/RET monoclonal antibody | Canine |
GM-Tg-bovg-T17566-Ab-1/ GM-Tg-bovg-T17566-Ab-2 | Anti-Bovine RET V804L/RET monoclonal antibody | Bovine |
GM-Tg-equg-T17566-Ab-1/ GM-Tg-equg-T17566-Ab-2 | Anti-Equine RET V804L/RET monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T17566-Ab-1/ GM-Tg-hg-T17566-Ab-2; GM-Tg-rg-T17566-Ab-1/ GM-Tg-rg-T17566-Ab-2; GM-Tg-mg-T17566-Ab-1/ GM-Tg-mg-T17566-Ab-2; GM-Tg-cynog-T17566-Ab-1/ GM-Tg-cynog-T17566-Ab-2; GM-Tg-felg-T17566-Ab-1/ GM-Tg-felg-T17566-Ab-2; GM-Tg-cang-T17566-Ab-1/ GM-Tg-cang-T17566-Ab-2; GM-Tg-bovg-T17566-Ab-1/ GM-Tg-bovg-T17566-Ab-2; GM-Tg-equg-T17566-Ab-1/ GM-Tg-equg-T17566-Ab-2 |
Products Name | Anti-RET V804L/RET monoclonal antibody |
Format | mab |
Target Name | RET V804L |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-RET V804L benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species RET/ RET V804L/ CDHF12 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLP001422 | human RET Lentivirus plasmid |
ORF Viral Vector | vGMLP001422 | human RET Lentivirus particle |
Target information
Target ID | GM-T17566 |
Target Name | RET V804L |
Gene ID | 5979,19713,24716,703466,403494,101101086,515924,100146791 |
Gene Symbol and Synonyms | c-Ret,CDHF12,CDHR16,HSCR1,MEN2A,MEN2B,MTC1,PTC,RET,RET-ELE1,RET51,RET9 |
Uniprot Accession | P07949,G3V9H8 |
Uniprot Entry Name | RET_HUMAN,RET_RAT |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | Non-Small Cell Lung Cancer, Prostate Cancer |
Gene Ensembl | ENSG00000165731 |
Target Classification | Kinase |
The target: RET V804L, gene name: RET, also named as CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC-ELE1, RET. This gene encodes a transmembrane receptor and member of the tyrosine protein kinase family of proteins. Binding of ligands such as GDNF (glial cell-line derived neurotrophic factor) and other related proteins to the encoded receptor stimulates receptor dimerization and activation of downstream signaling pathways that play a role in cell differentiation, growth, migration and survival. The encoded receptor is important in development of the nervous system, and the development of organs and tissues derived from the neural crest. This proto-oncogene can undergo oncogenic activation through both cytogenetic rearrangement and activating point mutations. Mutations in this gene are associated with Hirschsprung disease and central hypoventilation syndrome and have been identified in patients with renal agenesis. [provided by RefSeq, Sep 2017].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.